Biodesix Inc is a biotechnology company that specializes in providing diagnostic solutions primarily for patients with lung diseases, particularly lung cancer. The company focuses on developing and commercializing innovative blood-based tests that enable clinicians to make more informed decisions regarding the diagnosis, prognosis, and treatment of lung cancer. Their comprehensive suite of tests leverages advanced genomics and artificial intelligence to analyze biomarkers, helping to tailor personalized treatment plans for patients and improve overall outcomes. Through its commitment to precision medicine, Biodesix aims to enhance patient care in oncology by delivering actionable insights that guide therapy choices. Read More
LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference on Thursday, September 11, 2025.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.
LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on Thursday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)’s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy
Investors cheered a 4.7 million share insider purchase and rallied behind the company’s push toward Q4 EBITDA positivity, offsetting Scotiabank’s price target cut to $2 after a Q1 revenue miss and lowered 2025 guidance.
